LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

ELISA-Based Neonatal Screening Line Offers Menu of Eight Kits

By LabMedica International staff writers
Posted on 25 Jun 2018
Print article
Image: The new line of ELISA tests designed for neonatal screening is based on Dry Blood Spot (DBS) technology and comprises a menu of eight kits (Photo courtesy of Calbiotech).
Image: The new line of ELISA tests designed for neonatal screening is based on Dry Blood Spot (DBS) technology and comprises a menu of eight kits (Photo courtesy of Calbiotech).
A recently released line of ELISA tests for neonatal screening is based on Dry Blood Spot (DBS) technology and comprises a menu of eight kits. The kits are the newest diagnostic assays being introduced by Calbiotech (Spring Valley, CA, USA).

The Calbiotech catalog features over 200 diagnostic products including a full range of ELISA-based immunoassay kits focused on areas such as: thyroid hormones, fertility, steroids, diabetes, allergy, anemia, growth markers, bone metabolism, inflammatory diseases, cancer, cardiac diseases, drugs of abuse, autoimmune disorders, infectious diseases, and neonatal screening.

In addition, Calbiotech's Custom Development team crafts custom assays in a "Pipeline to Production" approach. To this end, the company has developed coated microplates, reagents, buffers, and other components for pharmaceutical companies, universities, and research centers in the United States and around the world. Rounding out its contribution to the diagnostics industry, Calbiotech also offers contract-manufacturing services that cover immunoassay development (microplates and magnetic beads), bulk coating of microplates, reagent preparation, including bottling, labeling and packaging.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more